Distinct myeloid-derived suppressor cell populations in human glioblastoma
Christina Jackson(Parker Institute for Cancer Immunotherapy), Drew M. Pardoll(Bloomberg (United States)), Michael Lim(Stanford University), Jennifer H. Elisseeff(Johns Hopkins University), Hongkai Ji(Johns Hopkins University), W. S. Zhan(Bloomberg (United States)), Jonathan D. Powell(Enzo Life Sciences (United States)), Elizabeth A. Thompson(North Carolina State University), Ajay Vaghasia(Sidney Kimmel Comprehensive Cancer Center), Arbor G. Dykema(Bloomberg (United States)), John Choi(Stanford University), Sadhana Bom(Bloomberg (United States)), Kate M. Jones(University of Pennsylvania), Landon J. Hansen(Duke Medical Center), Brandon Hwa-Lin Bergsneider(Stanford University), Chetan Bettegowda(Johns Hopkins University), Wenpin Hou(City University of New York), Christopher Cherry(Johns Hopkins University), Zhicheng Ji(Johns Hopkins University), Srinivasan Yegnasubramanian(Johns Hopkins University), Hao Zhang(Johns Hopkins University), Ming Zhang(Bloomberg (United States)), Fausto J. Rodríguez(University of California, Los Angeles), Rulin Wang(Sidney Kimmel Comprehensive Cancer Center), William Lee Wang(Stanford University), Runzhe Li(Bloomberg (United States)), Jon Weingart(Johns Hopkins University), Calixto‐Hope G. Lucas(Johns Hopkins University)
Cited by 86
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k